Presymptom

Founded as a spinout company in 2019, the technology was originally developed by the Defence Science and Technology Laboratory (DSTL), designed to identify and predict those who are at particular risk of developing sepsis, using a set of biomarkers. Presymptom’s technology has the potential to be directly relevant for Covid-19 patients, which will provide vital and life-saving information. The scientists involved in the development of the technology were awarded the The Sun’s 2018 “Millie” Innovation Award.

Licensee

Website

presymptom.com

Markets and products

Medical diagnostics, Medtech

Status

Active

Recent News